Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Horm Metab Res ; 45(10): 765-8, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23918686

RESUMO

The present study describes the preliminary results of the use of 99mTc-anti-TNF-α scintigraphy as a new diagnostic approach to evaluate patients presenting with Graves' ophthalmopathy (GO). Patients (n=25) presenting at different inflammatory stages of GO and 10 healthy volunteers underwent 99mTc-anti-TNF-α scintigraphy. Images were obtained 15 min after the intravenous injection of 370 MBq (10 mCi) 99mTc-anti-TNF-α. Planar images were obtained in a 256×256 matrix (each lasting 5 min) and single photon emission computed tomography (SPECT) scan lasting 13 min. Regions of interest (ROI) were drawn on the orbit and cerebral hemispheres. The uptake of 99m Tc-anti-TNF-α in these regions was compared and positive scintigraphy established when the ROI was >2.5. In addition, uptake for each positive exam was scored as either slight (2.6-5.1), moderate (5.2-7.6), or high (>7.6). In this pilot study, 69 orbits were evaluated (1 patient had only 1 eye), and 27 had a positive CAS (≥3/7). Scintigraphies were positive in 38 orbits. Comparing the results of the exams with CAS, a high sensitivity and negative predictive values were determined for scintigraphy (96.3% and 96.7%, respectively). However, the specificity and the positive predictive values were 71.4% and 68.4%, respectively, with an accuracy of 81.2%. The exclusion of examinations that were slightly positive from the analysis resulted in an improvement in test accuracy (95.5%). The preliminary results suggest that 99mTc-anti-TNF-α scintigraphy is a promising procedure for the evaluation of active orbital inflammation in GO.


Assuntos
Anticorpos , Oftalmopatia de Graves/diagnóstico por imagem , Tecnécio , Tomografia Computadorizada de Emissão de Fóton Único , Fator de Necrose Tumoral alfa/imunologia , Adulto , Olho/diagnóstico por imagem , Olho/patologia , Humanos , Inflamação/diagnóstico por imagem , Pessoa de Meia-Idade , Órbita/diagnóstico por imagem , Projetos Piloto , Valor Preditivo dos Testes , Projetos de Pesquisa , Sensibilidade e Especificidade , Índice de Gravidade de Doença
2.
Haemophilia ; 17(5): e985-9, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21388489

RESUMO

Recurrent haemarthroses often lead to chronic synovitis in patients with haemophilia and von Willebrand disease. Radioactive synovectomy with yttrium-90 (9°Y) citrate is frequently used to treat this complication, usually with good results. Since 2006, the Nuclear Energy Research Institute (IPEN, Sao Paulo, Brazil) has produced hydroxyapatite particles labelled with 9°Y for radioactive synovectomy. The aim of this study was to compare the results achieved by both forms of 9°Y in the treatment of haemophilic synovitis. We included 221 joints from 136 patients (age range: 6-20 years), treated by one of the two radiopharmaceuticals, at the Hemocenter of Mato Grosso, Brazil. The outcomes analysed were the annual frequency of haemarthrosis, articular pain and joint range of motion before and 1 year after RS. Similar results were achieved regardless of whether 9°Y hydroxyapatite or 9°Y citrate was used, and results were independent of the joint type, age, gender, radiologic stage and presence of inhibitors. 9°Y hydroxyapatite appears to be equivalent to the reference product 9°Y citrate in the treatment of chronic synovitis associated with bleeding disorders.


Assuntos
Citratos/uso terapêutico , Durapatita/uso terapêutico , Hemofilia A/complicações , Compostos Organometálicos/uso terapêutico , Sinovite/radioterapia , Radioisótopos de Ítrio/uso terapêutico , Adolescente , Artralgia/radioterapia , Brasil , Criança , Feminino , Hemartrose/complicações , Humanos , Masculino , Medição da Dor , Radiografia , Amplitude de Movimento Articular , Sinovite/diagnóstico por imagem , Sinovite/etiologia , Adulto Jovem
3.
Br J Radiol ; 81(961): 25-9, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18039720

RESUMO

The aim of this study was to investigate the feasibility of using a monoclonal antibody (OKT3) labelled with technetium-99m (99mTc) to monitor disease activity in patients with rheumatoid arthritis. We evaluated 38 patients who were diagnosed with rheumatoid arthritis and classified as Classes II and III after functional assessment (according to the revised criteria specified by the American College of Rheumatology). Two sets of planar anterior images of the patients' wrists, metacarpophalangeal and interphalangeal joints, elbows, shoulders and knees joints were obtained 1 h and 3 h after the injection of 99mTc-OKT3. The scintigraphic findings showed significant correlation (p<0.05) between the radiopharmaceutical accumulation of 99mTc-OKT3 and swollen joints, tender joints and the visual analogue scale. They were able to differentiate patients in remission from patients with active synovitis, according to DAS 28. In contrast, there was no correlation between the radiopharmaceutical accumulation and the patients' age, gender, duration of disease or erythrocyte sedimentation rate. A relatively high disease activity score of 28 joints (4.08+/-1.74) was found in the majority of patients. In conclusion, 99mTc-OKT3 scintigraphy is a reliable and objective method for detecting synovial activity, and can be used to observe disease prognosis.


Assuntos
Artrite Reumatoide/diagnóstico por imagem , Sinovite/diagnóstico por imagem , Adulto , Artrite Reumatoide/complicações , Sedimentação Sanguínea , Estudos de Viabilidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Muromonab-CD3 , Prognóstico , Cintilografia , Fator Reumatoide/sangue , Índice de Gravidade de Doença , Sinovite/etiologia , Tecnécio
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...